Renovascular hypertension from the BCR‐ABL tyrosine kinase inhibitor ponatinib

Volume: 22, Issue: 4, Pages: 678 - 682
Published: Mar 16, 2020
Abstract
Drug-induced hypertension is one of the commonest causes of secondary hypertension. In the last few years, secondary hypertension due to tyrosine kinase inhibitors, from the vascular endothelial growth factor class, has been recognized to be an important cause of hypertension, as well as proteinuria, and occasionally kidney dysfunction in some cases. Less well-recognized is that BCR-ABL tyrosine kinase inhibitors also have adverse vascular...
Paper Details
Title
Renovascular hypertension from the BCR‐ABL tyrosine kinase inhibitor ponatinib
Published Date
Mar 16, 2020
Volume
22
Issue
4
Pages
678 - 682
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.